Table 5.
Ongoing or future PARP inhibitor trials in BRCA 1/2-mutated (BRCAmut) breast and ovarian cancers.
| Trial | Study population | PARP inhibitor | Comparison therapy | ClinicalTrials.gov status |
|---|---|---|---|---|
| Phase III | Met or unresect BRCAutmut BC | BMN 673 | Physician’s choice – capecitabine, eribulin, gemcitabine, or vinorelbine | NCT01945775 Recruiting |
| Phase III | HER-2 negative met or advanced BRCAutmut BC | Niraparib | Physician’s choice (select from four active comparators) | NCT01905592 (BRAVO) Not yet open for recruitment |
| Phase III | PSens BRCAutmut or HGS OC w/prior CR and second CR/PR | Niraparib (maintenance) | Placebo | NCT01847274 Recruiting |
| Phase III | PSens BRCAutmut (stage III or IV) OC in first CR/PR | Olaparib (maintenance) | Placebo | NCT01844986 Not yet open for recruitment |
| Phase III | Relapsed PSens BRCAutmut OC w/prior CR and second CR/PR | Olaparib (maintenance) | Placebo | NCT01874353 Not yet open for recruitment |
| Phase II | Met or locally advanced BRCAutmut BC/OC | Rucaparib | None | NCT00664781 |
| Active, not recruiting | ||||
| Phase II Miller et al. (105) | BRCAutmut BC or BRCAtwt TNBC w/residual disease in adjuvant setting (after NAC/surgery) | Rucaparib + cisplatin | Cisplatin | NCT01074970 Ongoing, not recruiting |
| Phase I | Met or unresect BRCAutmut BC and OC | Veliparib | None | NCT01853306 |
| Recruiting | ||||
| Phase I/II | Relapsed PRes or partially PSens BRCAutmut EOC | Veliparib | None | NCT01472783 |
| Veli-BRCA | ||||
| Recruiting | ||||
| Phase II | Met or advanced BRCAutmut BC | Veliparib | Placebo and carboplatin, paclitaxel | NCT01506609 |
| Isakoff et al. (106) | Three arms, plus temozolomide, or carboplatin, paclitaxel | Recruiting | ||
| Phase II | Advanced or recur BRCAutmut EOC | Veliparib | None | NCT01540565 |
| Coleman et al. (107) | Ongoing, not recruiting | |||
| Phase I | BRCAutmut solid tumors (e.g., BC and OC) | Veliparib + oxaliplatin and capecitabine | None | NCT01233505 |
| Recruiting | ||||
| Phase I | Met or unresect BRCAutmut BC and OC | Veliparib + temozolomide | None | NCT00526617 |
| Completed |
met, metastatic; unresect, unresectable; BC, breast cancer, PSen, platinum-sensitive; HGS, high-grade serous; OC, ovarian cancer; CR, complete response; PR, partial response; BRCAwt, BRCA-wild type; TNBC, triple negative breast cancer; NAC, neoadjuvant chemotherapy; PRes, platinum-resistant; EOC, epithelial ovarian cancer; recur, recurrent.